Intra-Cellular Therapies Inc (ITCI) concluded trading on Wednesday at a closing price of $127.15, with 6.34 million shares of worth about $806.63 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 66.25% during that period and on January 22, 2025 the price saw a gain of about 0.51%. Currently the company’s common shares owned by public are about 106.00M shares, out of which, 99.30M shares are available for trading.
Stock saw a price change of 0.20% in past 5 days and over the past one month there was a price change of 46.62%. Year-to-date (YTD), ITCI shares are showing a performance of 52.24% which increased to 94.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.78 but also hit the highest price of $128.00 during that period. The average intraday trading volume for Intra-Cellular Therapies Inc shares is 1.89 million. The stock is currently trading 27.93% above its 20-day simple moving average (SMA20), while that difference is up 39.34% for SMA50 and it goes to 63.36% higher than SMA200.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) currently have 106.00M outstanding shares and institutions hold larger chunk of about 90.40% of that.
The stock has a current market capitalization of $13.51B and its 3Y-monthly beta is at 0.72. It has posted earnings per share of -$0.86 in the same period. It has Quick Ratio of 7.51 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ITCI, volatility over the week remained 0.58% while standing at 2.54% over the month.
Analysts are in expectations that Intra-Cellular Therapies Inc (ITCI) stock would likely to be making an EPS of -0.11 in the current quarter, while forecast for next quarter EPS is -0.14 and it is 0.18 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.4 which is 0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.3 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 57.40% while it is estimated to increase by 159.32% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on September 06, 2024 offering an Overweight rating for the stock and assigned a target price range of between $68 and $92 to it. Coverage by Robert W. Baird stated Intra-Cellular Therapies Inc (ITCI) stock as an Outperform in their note to investors on January 03, 2024, suggesting a price target of $83 for the stock. On December 11, 2023, TD Cowen Initiated their recommendations, while on April 20, 2023, Morgan Stanley Initiated their ratings for the stock with a price target of $80. Stock get a Neutral rating from Goldman on August 22, 2022.
